Ajinomoto Completes Acquisition of Althea Technologies
Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies.
Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies, a provider of biopharmaceutical development and manufacturing services.
According to a company statement, Ajinomoto acquired all the capital stock of Althea for a purchase price of approximately $175 million. Althea will become a fully consolidated subsidiary of Ajinomoto Co., Inc. operating under the company name Ajinomoto Althea, Inc.
Ajinomoto Co. is a global manufacturer of seasonings, processed foods, beverages, amino acids, pharmaceuticals, and specialty chemicals. Althea Technologies is a contract development and manufacturing organization located in San Diego, providing clinical and commercial product development services.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
